CUMBERLAND PHARMACEUTICALS INC
About CUMBERLAND PHARMACEUTICALS INC
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $44.5M
- Net income
- -$2.8M
- Total assets
- $76.8M
- Market cap
- $86.9M
- Gross margin
- 85.0%
- Operating margin
- -6.3%
- Net margin
- -6.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $44.5M
- Cost of revenue
- $6.7M
- Gross profit
- $37.9M
- Operating expenses
- $40.6M
- Operating income
- -$2.8M
- Income tax
- $40.3K
- Net income
- -$2.9M
- EPS (basic)
- $-0.19
- EPS (diluted)
- $-0.19
Balance sheet
- Total assets
- $76.8M
- Current assets
- $37.1M
- Total liabilities
- $52.3M
- Current liabilities
- $36.7M
- Shareholders’ equity
- $24.5M
Cash flow
- Operating cash flow
- $4.9M
- Investing cash flow
- -$4.7M
- Financing cash flow
- -$6.7M
- Net cash flow
- -$6.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $86.9M
- EPS (diluted)
- $-0.19
- Shares outstanding
- 14.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 11, 2009
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $2.8M in FY2025.
- Revenue grew 24% from FY2021 to FY2025.
- Gross margin of 85.0%, net margin -6.4%.
- Trading 5% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CUMBERLAND PHARMACEUTICALS INC.
Write a review
News about CUMBERLAND PHARMACEUTICALS INC
News & sentiment via Polygon.io
